Longeveron Inc. (LGVN) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several concerns: increasing expenses and net loss, a postponed BLA submission, and vague management responses in the Q&A. Despite potential partnerships and strategic plans, the financial health and uncertainties around funding and timelines overshadow positive aspects. The increase in research and development expenses and the net loss, coupled with the postponed BLA submission, contribute to a negative outlook. The lack of clear guidance and specific plans to expedite regulatory processes further dampens sentiment, leading to a prediction of a negative stock price movement.
Key Financial Performance
Revenues for the 9 months ended September 30, 2025 $0.8 million, a decrease of $1.0 million or 53% year-over-year. The decline was primarily due to decreased participant demand for the Bahamas Registry Trial and reduced demand for contract manufacturing services from a third-party client.
Clinical trial revenue $0.7 million, a decrease of $0.3 million or 36% year-over-year. This was attributed to decreased participant demand for the Bahamas Registry Trial.
Contract manufacturing revenue $0.2 million, a decrease of $0.6 million or 76% year-over-year. The decline was driven by reduced demand for contract manufacturing services from a third-party client.
General and administrative expenses $9.1 million, an increase of $1.7 million or 22% year-over-year. The increase was primarily related to higher personnel and related costs, including severance and equity-based compensation.
Research and development expenses $9.3 million, an increase of $3.2 million or 52% year-over-year. The rise was driven by a $1.8 million increase in personnel and related costs, a $1.2 million increase in supplies and costs associated with technology transfer, and a $0.2 million increase in amortization expense related to patent costs.
Net loss $17.3 million, an increase of $5.4 million or 45% year-over-year. This was due to higher general and administrative expenses and research and development costs.
Cash and cash equivalents as of September 30, 2025 $9.2 million. The company extended its cash runway into late Q1 2026 through disciplined capital allocation and operational decisions.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Laromestrocel: Progress in three programs addressing rare pediatric cardiovascular indications (HLHS and pediatric dilated cardiomyopathy) and chronic age-related indications (Alzheimer's disease and aging-related frailty).
ELPIS II Phase IIb study: Completed enrollment in June for HLHS, with results expected in Q3 2026. This is the largest placebo-controlled study in this rare disease population.
HLHS Program: Potential regulatory approval and commercialization pending ELPIS II results. The program addresses a significant unmet medical need with a large market opportunity.
Alzheimer's Disease Program: Positive Phase IIa results and alignment with FDA on pivotal Phase II/III trial design. Potential for partnerships to advance commercialization.
Financial Management: Extended cash runway into late Q1 2026 through disciplined spending. Exploring additional financing options, including grants and strategic collaborations.
Manufacturing Strategy: Shifted to third-party CMO for commercial manufacturing. Initiated technology transfer and proof-of-concept runs, with plans for larger-scale campaigns.
BLA Preparedness: Focused on HLHS BLA readiness, with structured spending to optimize delivery of ELPIS II results. Full BLA filing expected in 2027.
Partnership Opportunities: Evaluating partnerships across all indications, including HLHS and Alzheimer's, to support development and commercialization.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Financial Stability: The company acknowledges risks in its current financial situation, with cash runway extended only into late Q1 2026. Future financing opportunities are not guaranteed, and failure to secure additional funding could materially impact operations and delay strategic objectives.
Revenue Decline: Revenues for the first nine months of 2025 decreased by 53% compared to 2024, driven by reduced demand for the Bahamas Registry Trial and contract manufacturing services. This decline could impact the company's ability to fund its operations and strategic initiatives.
Increased Expenses: General and administrative expenses increased by 22%, and research and development expenses rose by 52% compared to the same period in 2024. These rising costs contribute to a higher net loss, which increased by 45% year-over-year.
Regulatory and Development Risks: The company faces challenges in meeting regulatory and manufacturing milestones for its BLA submission for HLHS, now delayed to 2027. Any further delays or failures in clinical trials could jeopardize the approval and commercialization timeline.
Market and Competitive Risks: The company operates in a highly competitive and capital-intensive field of stem cell therapy. Failure to demonstrate the efficacy and safety of its therapies in pivotal trials could impact its market position and ability to attract partners or investors.
Operational Risks: The company is transitioning to third-party commercial manufacturing, which introduces risks related to technology transfer, process validation, and reliance on external partners. Any issues in these areas could delay production and regulatory approvals.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
HLHS Program: The company is focused on delivering clinical trial results from ELPIS II, a pivotal Phase IIb study in HLHS, with results expected in Q3 2026. Pending positive results, there is a clear path to potential regulatory approval and commercialization.
Financial Resources: The company is actively seeking additional financing through capital raises, grants, and strategic collaborations to support its development programs. Current cash runway extends into late Q1 2026, with plans to utilize an at-the-market financing facility if needed.
BLA Preparedness: The company is preparing for a Biologics License Application (BLA) submission for HLHS in 2027, contingent on successful ELPIS II trial results. Spending has been structured to deliver critical milestones while extending the cash runway.
Alzheimer's Disease Program: The company is exploring collaborations and partnerships for advancing laromestrocel in Alzheimer's disease, following positive Phase IIa results and alignment with the FDA on a pivotal Phase II/III trial design.
Manufacturing Readiness: The company has initiated technology transfer activities with a third-party CMO for commercial manufacturing. Larger-scale manufacturing campaigns are planned to support future commercial production.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you elaborate on the business advisability of identifying potential partners for commercialization in rare, ultra-rare conditions like HLHS or PCM?
A:The company is exploring partnerships both in and outside the U.S. for commercialization in rare pediatric diseases. While they are prepared for self-commercialization due to the niche market, they recognize the value of partnerships for cost savings and revenue ramp-up. They are considering various partnership structures, including commercial partnerships and future development collaborations, depending on the quality of data from the ELPIS II study.
Q:Can you elaborate on dementia and Lewy body dementia as a potential additional indication for laromestrocel?
A:The company is focused on mild cognitive disease and Alzheimer's disease in their current trials. While Lewy body dementia shares a common pathophysiology of neuroinflammation with Alzheimer's, the company would consider exploring it if there is solid scientific rationale and a development partner with expertise in the area. However, their immediate focus remains on Alzheimer's.
Q:What are your expectations for the placebo and treatment groups for the composite endpoint in ELPIS II?
A:The composite endpoint includes all-cause mortality, transplant-free survival, and hospitalization. The company is designing the endpoint based on prior data from the ELPIS I trial and real-world evidence to ensure it is clinically meaningful. They are focused on outcomes that are significant for patients, parents, and regulatory approval.
Q:Why has the BLA submission timeline been postponed to 2027 instead of late 2026?
A:The postponement is due to operational decisions to optimize spending in CMC and timing. While conversations with the FDA may start earlier, a full submission by 2026 is unlikely. The company is working to secure additional funding to potentially accelerate the timeline. The delay is not related to clinical trial results or CMC findings, which are on track.
Q:What steps can you take to increase the M&A appeal of Longeveron in the rare disease space?
A:The company is emphasizing the value of its lead indication, HLHS, and its pipeline in rare pediatric diseases. They aim to ensure that any M&A or partnership discussions reflect the full value of the company. They are also focusing on communicating the unmet needs in congenital heart defects to potential partners.
Q:Does the success of Mesoblast in GvHD impact how you view the value of laromestrocel in HLHS?
A:The company sees significant value in laromestrocel for HLHS, particularly in survival, hospitalization reduction, and transplant-free survival. While Mesoblast's success in cell therapy is encouraging, the company views HLHS as a unique value proposition.
Q:How important is the long-term follow-up data from ELPIS I for payer conversations?
A:The company believes the long-term follow-up data from ELPIS I is important for demonstrating the persistence of outcomes, which could be valuable in payer conversations. However, they cannot predict its exact impact on reimbursement decisions.
Q:Have you explored ways to expedite the BLA pathway, such as the Commissioner's National Priority Voucher program?
A:The company is leveraging its designations to have productive conversations with the FDA and is exploring all options to expedite the BLA pathway. They are also advocating for the extension of the priority review voucher system, which they believe is critical for rare disease innovation.
Q:Review of Unclear Management Responses
A:Management avoided providing specific expectations for the placebo and treatment groups in ELPIS II, citing the use of prior data and real-world evidence without detailing numerical targets. Additionally, while they discussed the BLA timeline delay, they did not provide a clear plan for securing additional funding or specific steps to accelerate the timeline. Their response to the potential use of the Commissioner's National Priority Voucher program was also vague, focusing instead on general advocacy for the priority review voucher system.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Chief Science
Co Founder
Dr Chief
ELPIS II
Executive Chairman
Founder Chief
HLHS BLA
Interim Chief
Longeveron stem
Miami cGMP
Officer Executive
Science Officer
action cash
cGMP facility
capital raise
cash runway
cell research
child
client
contract manufacturing
delivery study
development approval
milestone
month decrease
month period
opportunity contract
option grant
production
raise funding
result action
rigor
runway BLA
service party
situation
spend delivery
technology transfer
trial result
LGVN Transcript
Longeveron Inc. (LGVN) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call summary shows a positive financial performance with a 15% revenue increase and reduced net loss, but lacks strategic updates or guidance. The absence of strategic discussions or clear future outlooks, combined with no significant shareholder return announcements, suggests a neutral market reaction. The company's small market cap could lead to more volatility, but the lack of new information tempers any strong positive or negative sentiment.
Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript
Unknown3-17
The earnings call summary indicates declining revenue, increased expenses, and a significant net loss, all of which are negative financial indicators. The Q&A reveals management's uncertainty in monetizing PRVs and dependence on strategic partnerships, which are risky. Despite some positive developments in manufacturing and potential partnerships, the overall financial health is concerning. The lack of clear guidance and reliance on future approvals adds to the negative sentiment. Given these factors and the absence of a market cap to gauge volatility, a strong negative stock price movement is likely.
Longeveron Inc. (LGVN) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call reveals several concerns: increasing expenses and net loss, a postponed BLA submission, and vague management responses in the Q&A. Despite potential partnerships and strategic plans, the financial health and uncertainties around funding and timelines overshadow positive aspects. The increase in research and development expenses and the net loss, coupled with the postponed BLA submission, contribute to a negative outlook. The lack of clear guidance and specific plans to expedite regulatory processes further dampens sentiment, leading to a prediction of a negative stock price movement.
Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call summary indicates a decrease in revenue and increased expenses, leading to a higher net loss. The Q&A section reveals uncertainties in pricing strategies and potential market risks. Although there are positive regulatory milestones and strategic initiatives, the financial challenges and lack of clear guidance on pricing strategies suggest a negative sentiment. Additionally, the public offering and the need for further funding introduce concerns about financial health. Overall, these factors contribute to a negative outlook for the stock price over the next two weeks.
LGVN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
